Condition: Breast Cancer · Sponsor: The Netherlands Cancer Institute
This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery
This description comes directly from the study's public registry record.
F.H. van Duijnhoven, MD, PhD · +31(0)20 5126170 · f.v.duijnhoven@nki.nl
J.P. van Olmen, Drs · 020-5129111 · j.v.olmen@nki.nl
Always discuss trial participation with your own doctor first.
| Antoni van Leeuwenhoek | Amsterdam, North Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05416164